Abstract
More than a year after the COVID-19 pandemic has been declared, the need still exists for accurate, rapid, inexpensive and non-invasive diagnostic methods that yield high specificity and sensitivity towards the current and newly emerging SARS-CoV-2 strains. Several studies have since established saliva as a more amenable specimen type for early detection of SARS-CoV-2 as compared to nasopharyngeal swabs. Considering the limitations and high demand for COVID-19 testing, we employed MALDI-ToF mass spectrometry for the analysis of 60 gargle samples from human donors and compared the spectra with their COVID-19 status. Several standards including isolated human serum immunoglobulins and controls such as pre-COVID-19 saliva and heat inactivated SARS-CoV-2 virus were simultaneously analyzed to provide a relative view of the saliva and viral proteome as they would appear in this works methodology. Five potential biomarker peaks were established that demonstrated high concordance with COVID-19 positive individuals. Overall, the agreement of these results with RT-qPCR testing on NP swabs was no less than 90% for the studied cohort, which consisted of young and largely asymptomatic student athletes. From a clinical standpoint, the results from this pilot study are promising and suggest that MALDI-ToF can be used to develop a relatively rapid and inexpensive COVID-19 assay.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was generously supported by the Division of Research and Innovation Partnerships, Northern Illinois University
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Northern Illinois University, IRB approval obtained on August 12, 2020 University of Illinois at Chicago, IRB approval obtained on February 11, 2021
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# co-first authors
Data Availability
Data will be made available as supplemental material with the peer-reviewed and accepted manuscript or upon request
Abbreviations
- ACE2
- angiotensin-converting enzyme 2
- AUC
- area under the curve
- COVID-19
- coronavirus disease 2019
- Ct
- cycle threshold
- DTT
- dithiothreitol
- E Protein
- envelope protein
- EUA
- emergency use authorization
- FDA
- food and drug administration
- IgA
- immunoglobulin A
- IgG
- immunoglobulin G
- IgM
- immunoglobulin M
- LoD
- limit of detection
- LC-MS
- liquid chromatography mass spectrometry
- M Protein
- membrane protein
- MALDI-ToF MS
- matrix-assisted laser desorption/ionization-time of flight mass spectrometry
- N Protein
- nucleocapsid protein
- NP
- nasopharyngeal
- RBD
- receptor binding domain
- RNA
- ribonucleic acid
- ROC
- receiver operating characteristic
- RT-qPCR
- reverse transcriptase quantitative polymerase chain reaction
- S Protein
- spike protein
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- VEP
- viral envelope protein
- WHO
- world health organization
